About Molecure
Molecure is a company based in Warsaw (Poland) founded in 2012. The company has 102 employees as of December 31, 2024. Molecure offers products and services including Small Molecule Drugs and RNA Targeting Platform. Molecure operates in a competitive market with competitors including Moderna, Merck, Roivant Sciences, AbbVie and Gilead, among others.
- Headquarter Warsaw, Poland
- Employees 102 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Molecure Sa
-
Annual Revenue
Not available
-
Net Profit
-$7.6 M (USD)-10.27as on Dec 31, 2024
-
EBITDA
-$7.24 M (USD)7.28as on Dec 31, 2024
-
Latest Funding Round
$241.13 K (USD), Grant
May 01, 2024
-
Investors
HHS
& 1 more
-
Employee Count
102
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Molecure
Molecure is a publicly listed company on the GPW with ticker symbol MOC in Poland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Molecure
Molecure offers a comprehensive portfolio of products and services, including Small Molecule Drugs and RNA Targeting Platform.
Develops drugs targeting proteins for treating incurable diseases.
Platform for modulating mRNA to create drug candidates.
People of Molecure
Unlock access to complete
Unlock access to complete
Funding Insights of Molecure
Investors in Molecure
Molecure has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS and New Europe Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Molecure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Molecure
Investment portfolio details for Molecure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Molecure
Detailed financials for Molecure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Molecure Comparisons
Peer comparison for Molecure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Molecure
Molecure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Merck, Roivant Sciences, AbbVie and Gilead, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Biopharmaceutical research and drug development are conducted globally by AbbVie.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
Detailed competitors of Molecure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Molecure
Complete news archive for Molecure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Molecure
Molecure was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Molecure is headquartered in Warsaw, Poland.
Marcin Jan Szumowski is the current CEO of Molecure.
As of Dec 31, 2024, the latest employee count at Molecure is 102.
Molecure was established in 2012 in Warsaw, Poland, within the biotechnology sector. Small molecule drugs are developed to target cancer and inflammatory diseases. An mRNA targeting discovery platform is utilized to modulate protein and RNA targets, addressing cancer, fibrotic, and inflammatory conditions. Operations focus on drug discovery and development for these therapeutic areas.
Molecure's top competitors include Merck, Moderna and Roivant Sciences.
Molecure offers Small Molecule Drugs and RNA Targeting Platform.
Yes, Molecure is publicly traded on GPW under the ticker symbol MOC.
Molecure has 2 investors. Key investors include HHS, and New Europe Ventures.
The ticker symbol of Molecure is MOC on GPW.